Leukaemia Forecast Report 2017-2027: 10 year Forecasts in 18 Major Markets

Dublin, Jan. 30, 2017 -- Research and Markets has announced the addition of the "Leukaemia Forecast in 18 Major Markets 2017-2027" report to their offering.

This report provides the current incidence population for Leukaemia across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Leukaemia refers to a group of cancers which originate in the bone marrow; they result in the overproduction of abnormal white blood cells. This limits the bone marrows ability to produce normal and fully mature white blood cells. Leukaemia classification is based on the speed of disease progression and the type of cells involved.

The main subtypes are myeloid and monocytic, lymphoid or other; these can then be further subdivided into groups such as 'Acute' or 'Chronic'. Acute and chronic refer to the speed of disease progression. Whereas, myeloid, monocytic and lymphoid refer to the cell type affected.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Leukaemia have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Leukaemia include:

- Haemolytic Anaemia
- Diabetes
- Frequent infections
- Headaches
- Cachexia

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line Incidence for Leukaemia

10. Type of Leukaemia

11. Lymphocytic Leukaemia

12. Myeloid & Monocytic Leukaemia

13. Other Types of Leukaemia

14. Treatment Rates

15. Abbreviations used in the Report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/pw5ntj/leukaemia

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Leukemia Drugs